TAP1

Antigen peptide transporter 1 · Q03518 · TAP1 on Sugi Atlas →

0 patent compounds predicted against TAP1, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to TAP1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
TEIPP Immunotherapy in Patients With NSCLC PHASE1/PHASE2COMPLETED
Study of MAGE-3/Melan-A/gp 100/NA17 and rhIL-12 With/Out Low Dose IL-2 in Metastatic Melanoma PHASE2COMPLETED
MB-dNPM1-TCR.1 in Relapsed/Refractory AML PHASE1/PHASE2RECRUITING
Wilm's Tumor 1 Protein Vaccine to Treat Cancers of the Blood PHASE1/PHASE2COMPLETED
Radiation, Chemotherapy, Vaccine and Anti-MART-1 and Anti-gp100 Cells for Patients With Metastatic Melanoma PHASE2COMPLETED
Valuation of the Safety and Efficacy of Combination of Cryoablation and Dendric Cell/Cytokine-induced Killers Cells Treatment for Advanced Liver Cancers PHASE1/PHASE2UNKNOWN
Aerosolized Azacytidine as Epigenetic Priming for Bintrafusp Alfa-Mediated Immune Checkpoint Blockade in Patients With Unresectable Pulmonary Metastases From Sarcomas, Germ Cell Tumors, or Epithelial Malignancies PHASE1/PHASE2WITHDRAWN
Adoptive Transfer of Specific Melanoma Antigens CD8+ T Cells in Metastatic Melanoma Patients: a Phase I/II Study PHASE1/PHASE2COMPLETED
Phase I/II Study of Vaccination With Antigen Loaded Dendritic Cells (DCs) in Hormone-Refractory Prostate Cancer PHASE1/PHASE2COMPLETED
Study of Gene Modified Immune Cells in Patients With Advanced Melanoma PHASE2COMPLETED
Vaccine Therapy in Treating Patients With Liver Cancer PHASE1/PHASE2COMPLETED
Consolidation Therapy in Patients With Metastatic Solid Malignancies PHASE1/PHASE2WITHDRAWN
Dendritic Cells for Immunotherapy of Metastatic Endometrial Cancer Patients PHASE2COMPLETED
Phase 1 Study Of Intrathecal Cellular Adoptive Immunotherapy Using Autologous CD8+ Antigen-Specific T Cells For Patients With Leptomeningeal Melanoma PHASE1NOT_YET_RECRUITING
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant PHASE1RECRUITING
Personalized Adoptive Cellular Therapy Targeting MDS Stem Cell Neoantigens (PACTN) PHASE1UNKNOWN
Dose Escalation Study of Immunomodulatory Nanoparticles PHASE1ACTIVE_NOT_RECRUITING
Dose Escalation Trial of WT1-Sensitized T Cells for Residual or Relapsed Leukemia After Allogeneic Hematopoietic Progenitor Cell Transplantation PHASE1COMPLETED
Phase I Trial of LMP2 Antigen-specific TCR T-cell Therapy for Recurrent and Metastatic NPC Patients PHASE1UNKNOWN
T Cell Receptor-transduced T Cells Targeting NY-ESO-1 for Treatment of Patients With NY-ESO-1- Expressing Malignancies PHASE1UNKNOWN
NY-ESO-1-redirected T Cells in Patients With Advanced Melanoma and Sarcoma PHASE1RECRUITING
NY-ESO-1 TCR-T Cells for NY-ESO-1 Positive Subjects With Advanced Solid Tumors PHASE1RECRUITING
Autologous T Cells Targeting HPV16 HPV18 & Survivin in Patients With R/R HPV-related Oropharyngeal Cancers PHASE1NOT_YET_RECRUITING
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer PHASE1RECRUITING
0804 GCC: MAGE-A3/HPV 16 Vaccine for Squamous Cell Carcinoma of the Head and Neck PHASE1COMPLETED
A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1ᶜ²⁵⁹T in HLA-A2+ Patients With Synovial Sarcoma PHASE1COMPLETED
TCR-T Cells for the Treatment NY-ESO-1-positive Advanced Solid Tumors EARLY_PHASE1UNKNOWN
COLONYVAQ™, a Quantum-Classical Guided Personalized Neoantigen Vaccine for MSS Stage III Colorectal Cancer EARLY_PHASE1RECRUITING
Pilot Study of Neoantigen Peptides for the Treatment of Neoplasms EARLY_PHASE1COMPLETED
LANDscape MApping of Epitopes and T Cell Receptors for Selected Cancers nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a TAP1 binder may also engage these)

ProteinNameSimilarity
P36370 1.000 P36370 →
Q28433 1.000 Q28433 →
P21958 1.000 P21958 →
P36372 0.994 P36372 →
O88269 0.993 O88269 →
Q5T3U5 0.991 Q5T3U5 →
Q9R1S7 0.991 Q9R1S7 →
O70595 0.990 O70595 →
O95255 0.990 O95255 →
P36371 0.988 P36371 →
TAP2 Antigen peptide transporter 2 0.987 landscape →
Q8R4P9 0.985 Q8R4P9 →
ABCC3 ATP-binding cassette sub-family C member 3 0.984 landscape →
Q91W34 0.983 Q91W34 →
Q9NP58 0.982 Q9NP58 →
Q5R8F6 0.981 Q5R8F6 →
Q8K0H7 0.980 Q8K0H7 →
B2RX12 0.980 B2RX12 →
Q3ZBE0 0.979 Q3ZBE0 →
Q7TNJ2 0.979 Q7TNJ2 →
Q91V24 0.979 Q91V24 →
P54777 0.979 P54777 →
Q9QYJ4 0.978 Q9QYJ4 →
P51839 0.978 P51839 →
Q9NP78 0.978 Q9NP78 →
O88563 0.977 O88563 →
A6H751 0.977 A6H751 →
Q9NRK6 0.977 Q9NRK6 →
Q924H9 0.977 Q924H9 →
Q68DD2 0.977 Q68DD2 →